Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.40 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160129 | 0.87 | OPRM1 (0.51) | KMT2AMEN1OPRM1OPRL1KCNA3 | |
| SCHEMBL4869393 | 0.82 | EPHX1 (0.42) | KMT2AMEN1OPRM1OPRL1EPHX1 | |
| SCHEMBL4867891 | 0.81 | KMT2A (0.41) | KMT2AMEN1SIGMAR1OPRM1OPRL1 | |
| SCHEMBL4864032 | 0.81 | DRD2 (0.44) | KMT2AMEN1EPHX1 | |
| SCHEMBL4053293 | 0.79 | KMT2A (0.50) | KMT2ASIGMAR1OPRM1OPRL1KCNA3 | |
| SCHEMBL2981366 | 0.78 | EPHX2 (0.50) | KMT2AMEN1OPRM1OPRL1EPHX1 | |
| SCHEMBL17591720 | 0.78 | KMT2A (0.69) | KMT2AMEN1SIGMAR1EPHX1L3MBTL1 | |
| SCHEMBL8693601 | 0.75 | EPHX1 (0.64) | KMT2AMEN1EPHX1EPHX2 | |
| SCHEMBL25048413 | 0.74 | CA1 (0.60) | SIGMAR1L3MBTL1IDO1 | |
| SCHEMBL16095344 | 0.74 | KMT2A (0.60) | KMT2AMEN1SIGMAR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439394-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2008-10-21 | — | — | US | claimed |
| US-20070117803-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-24 | — | — | US | claimed |
| EP-1751090-B1 | ACID DERIVATIVES OF SUBSTITUTED CYCLOHEXYL-1,4-DIAMINES | GRUENENTHAL GMBH (DE) | 2014-10-08 | — | — | EP | disclosed |
| US-7439394-B2 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20070117803-A1 | Cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117803-A1 | Cyclohexyl-1,4-diamine compounds | PKD1, DDC, DPYD | KMT2A 3604/4885MEN1 713/4885SIGMAR1 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.